PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19891554-0	2009	Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.	Sulfonylurea Compounds	101-114	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	12-18	
19891554-2	2009	Impaired metabolism of sulfonylureas due to gene polymorphisms in the metabolic enzyme CYP2C9 might lead to hypoglycemia.	Sulfonylurea Compounds	23-36	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93	
19891554-3	2009	In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide.	Sulfonylurea Compounds	178-191	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	56-62	
19891554-3	2009	In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide.	Sulfonylurea Compounds	178-191	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	79-85	
19891554-3	2009	In the present study we explored the association of the CYP2C9 variant alleles CYP2C9*2 and CYP2C9*3 with the incidence of hypoglycemic events in diabetic patients receiving the sulfonylureas glimepiride and gliclazide.	Sulfonylurea Compounds	178-191	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	79-85	
19891554-9	2009	In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011).	Sulfonylurea Compounds	53-65	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110	
19891554-9	2009	In a model adjusted for age, BMI, mean daily dose of sulfonylurea, duration of T2DM and renal function, CYP2C9*1/*3 genotype increased the hypoglycemia risk in response to sulfonylurea (odds ratio: 1.687; p = 0.011).	Sulfonylurea Compounds	172-184	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	104-110	
19891554-12	2009	Furthermore, in T2DM patients, CYP2C9*3 increases the risk of hypoglycemia when they are treated with sulfonylureas, possibly due to impaired metabolism of these drugs.	Sulfonylurea Compounds	102-115	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	31-37	
19891554-13	2009	CYP2C9 genotyping might thus be a useful tool for predicting adverse effects caused by sulfonylureas and help clinicians in safer prescribing of oral hypoglycemic agents.	Sulfonylurea Compounds	87-100	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6